Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine

Summary

This Phase 3 study is intended to assess clinical lot-to-lot consistency by evaluating and comparing the immunogenicity of three consecutively manufactured lots of Coronavirus-like Particle (CoVLP).

Timeline

Start

2021-11-22

Primary completion

2022-05-31

Completion

2022-05-31

Outcome

Outcome not reported

Stopped: “Further development terminated”

Drugs

Indications